Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Metabasis reports positive results from phase Ib clinical trial of MB-07811 for hyperlipidemia

Jan. 8, 2008

Sangamo initiates phase II clinical trial of SB-509 in diabetic neuropathy

Jan. 8, 2008

Novel therapeutic compounds for metabolic disorders described in recent patent literature

Jan. 8, 2008

BioMarin and Genzyme restructure their joint venture for Aldurazyme for MPS I

Jan. 8, 2008

Brain cholesterol reduction with LXR agonist beneficial in experimental Niemman-Pick disease

Jan. 8, 2008

Positive results found in QuatRx's pivotal postmenopausal vaginal syndrome study

Jan. 7, 2008

Takeda submits NDA for alogliptin in the U.S.

Jan. 4, 2008

Recent patents describe new antidiabetic agents

Jan. 3, 2008

Targeting galectin-1 may be useful to prevent pregnancy loss

Jan. 3, 2008

Galvus obtains positive opinion regarding E.U. prescribing information changes

Dec. 31, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Roche secures CE mark for Alzheimer’s blood test
BioWorld
Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 blood test designed to rule in and rule out amyloid pathology, a hallmark of...